|
Carcinogenesis
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
<i>In vivo</i> tumorigenesis experiments showed that inhibition of SOX12 expression significantly suppressed the growth of xenograft tumors.
|
28979676 |
2017 |
|
Neoplasms
|
0.030 |
AlteredExpression
|
group |
BEFREE |
<i>In vivo</i> tumorigenesis experiments showed that inhibition of SOX12 expression significantly suppressed the growth of xenograft tumors.
|
28979676 |
2017 |
|
Developmental delay (disorder)
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
SOX12 and NRSN2 are candidate genes for 20p13 subtelomeric deletions associated with developmental delay.
|
24019301 |
2013 |
|
Global developmental delay
|
0.010 |
Biomarker
|
disease |
BEFREE |
SOX12 and NRSN2 are candidate genes for 20p13 subtelomeric deletions associated with developmental delay.
|
24019301 |
2013 |
|
leukemia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
SOX12 may be involved in leukaemia progression by regulating the expression of β-catenin and then interfering with TCF/Wnt pathway, which may be a target for AML.
|
27858992 |
2017 |
|
Leukemia, Myelocytic, Acute
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
SOX12 was preferentially expressed in CD34<sup>+</sup> cells in AML patients.
|
27858992 |
2017 |
|
Malignant Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
Sox12 Is a Cancer Stem-Like Cell Marker in Hepatocellular Carcinoma.
|
29127951 |
2017 |
|
Primary malignant neoplasm
|
0.010 |
Biomarker
|
group |
BEFREE |
Sox12 Is a Cancer Stem-Like Cell Marker in Hepatocellular Carcinoma.
|
29127951 |
2017 |
|
Colitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Sox12 promotes T reg differentiation in the periphery during colitis.
|
30190287 |
2018 |
|
Malignant neoplasm of colon and/or rectum
|
0.010 |
Biomarker
|
disease |
BEFREE |
SOX12 promotes colorectal cancer cell proliferation and metastasis by regulating asparagine synthesis.
|
30858360 |
2019 |
|
Malignant tumor of colon
|
0.010 |
Biomarker
|
disease |
BEFREE |
A novel genome-wide in vivo screen for metastatic suppressors in human colon cancer identifies the positive WNT-TCF pathway modulators TMED3 and SOX12.
|
24920608 |
2014 |
|
Colon Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
A novel genome-wide in vivo screen for metastatic suppressors in human colon cancer identifies the positive WNT-TCF pathway modulators TMED3 and SOX12.
|
24920608 |
2014 |
|
Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
Administration of L-asparaginase decreased SOX12-mediated tumor growth and metastasis.
|
30858360 |
2019 |
|
Neoplasm Metastasis
|
0.050 |
Biomarker
|
phenotype |
BEFREE |
Administration of L-asparaginase decreased SOX12-mediated tumor growth and metastasis.
|
30858360 |
2019 |
|
Liver carcinoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
CDK4 and IGF2BP1 were among the top 20 SOX12 co-upregulated genes in HCC, which have well characterized enhancing the effect on HCC cell growth, invasion, and metastasis.
|
28975985 |
2017 |
|
Neoplasm Metastasis
|
0.050 |
AlteredExpression
|
phenotype |
BEFREE |
CDK4 and IGF2BP1 were among the top 20 SOX12 co-upregulated genes in HCC, which have well characterized enhancing the effect on HCC cell growth, invasion, and metastasis.
|
28975985 |
2017 |
|
Papillary thyroid carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Consequently, we found that NR2F1-AS1 and SOX12 levels were elevated in PTC, whereas miR-423-5p was downregulated in PTC cells.
|
31692033 |
2020 |
|
Colorectal Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Downregulation of GLS, GOT2, and ASNS blocked SOX12-mediated CRC cell proliferation and metastasis, whereas ectopic expression of GLS, GOT2, and ASNS attenuated the SOX12 knockdown-induced suppression of CRC progression.
|
30858360 |
2019 |
|
Tumor Cell Invasion
|
0.050 |
Biomarker
|
phenotype |
BEFREE |
Finally, the mRNA and protein levels of cell growth (PCNA and Cyclin E), apoptosis (Bcl-2 and Bax), invasion (matrix metalloproteinase-9) and epithelial-mesenchymal transition (EMT; Twist1 and E-cadherin) related moderators were affected by SOX12 knockdown.
|
28979676 |
2017 |
|
Mantle cell lymphoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Here we report the variable expression of SOX4 and high expression of SOX12 in MCL compared to non-malignant tissue.
|
23466598 |
2013 |
|
Malignant neoplasm of stomach
|
0.010 |
Biomarker
|
disease |
BEFREE |
In conclusion, SOX12 is a novel prognostic biomarker and regulator of GC metastasis.
|
30922917 |
2019 |
|
Stomach Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
In conclusion, SOX12 is a novel prognostic biomarker and regulator of GC metastasis.
|
30922917 |
2019 |
|
Neoplasm Metastasis
|
0.050 |
Biomarker
|
phenotype |
BEFREE |
In conclusion, SOX12 is a novel prognostic biomarker and regulator of GC metastasis.
|
30922917 |
2019 |
|
Mantle cell lymphoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
In this study we found variable expression of SOX11, SOX4 and SOX12 mRNA in mantle cell lymphoma cell lines.
|
21124928 |
2010 |
|
Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In this study we found variable expression of SOX11, SOX4 and SOX12 mRNA in mantle cell lymphoma cell lines.
|
21124928 |
2010 |